Loading
A phase 3 trial testing Ifupinostat in diffuse large B-cell lymphoma, now recruiting.
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma is a phase 3 interventional study registered as NCT06792253, led by BeBetter Med, and recruiting on the registry. Official title: Phase Ⅲ Clinical Trial Comparing BEBT-908 Combined With Rituximab (R) to Standard of Care for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Planned enrolment is 416 participants (estimated). The study started in 2025-01-06 and primary completion is expected in 2028-12-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/